

**IN THE CLAIMS:**

Claim 1 (original): A combination which comprises an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a metal salt, wherein the metal salt is formulated to release in the terminal ileum, caecum and/or the colon.

Claim 2 (original): A combination according to claim 1 wherein the metal salt is a calcium salt.

Claim 3 (currently amended): A combination according to claim 1 ~~either of claims 1 or 2~~ wherein the metal salt is calcium phosphate.

Claim 4 (currently amended): A combination according to claim 1 ~~any one of claims 1—3~~ wherein the IBAT inhibitor is a benzothiepine.

Claim 5 (currently amended): A combination according to claim 1 ~~any one of claims 1—3~~ wherein the IBAT inhibitor is selected from:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(carboxymethyl) carbamoyl]methyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(carboxymethyl)carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(2-sulphoethyl) carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(2-carboxyethyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(2-carboxyethyl) carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(5-carboxypentyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(2-carboxyethyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{ $\alpha$ -[*N'*-(2-sulphoethyl) carbamoyl]-2-fluorobenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(R)-(2-hydroxy-1-carboxyethyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(R)-(2-hydroxy-1-carboxyethyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- $\alpha$ -(*N'*-{(R)-1-[*N''*-(R)-(2-hydroxy-1-carboxyethyl) carbamoyl]-2-hydroxyethyl} carbamoyl)benzyl] carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{ $\alpha$ -[*N'*-(carboxymethyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{ $\alpha$ -[*N'*-((ethoxy)(methyl)phosphorylmethyl) carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-(N'-\{2-[(\text{hydroxy})(\text{methyl})\text{phosphoryl}]\text{ethyl}\}\text{carbamoyl}]\text{benzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,5-benzothiazepine};$
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-[N'-(2\text{-methylthio-1-carboxyethyl})\text{carbamoyl}]\text{benzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,5-benzothiazepine};$
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-(N'-\{2-[(\text{methyl})(\text{ethyl})\text{phosphoryl}]\text{ethyl}\}\text{carbamoyl})-4\text{-hydroxybenzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,5-benzothiazepine};$
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-(N'-\{2-[(\text{methyl})(\text{hydroxy})\text{phosphoryl}]\text{ethyl}\}\text{carbamoyl})-4\text{-hydroxybenzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,5-benzothiazepine};$
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-[(R)-N'-(2\text{-methylsulphinyl-1-carboxyethyl})\text{carbamoyl}]\text{benzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,5-benzothiazepine};$  and
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8- $\{N-[(R)-\alpha-[N'-(2\text{-sulphoethyl})\text{carbamoyl}]-4\text{-hydroxybenzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,5-benzothiazepine};$
- or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Claim 6 (currently amended): A combination according to claim 1 ~~any one of claims 1—3~~ wherein the IBAT inhibitor is selected from:

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-[N-((R)-1\text{-carboxy-2-methylthio-ethyl})\text{carbamoyl}]-4\text{-hydroxybenzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,2,5-benzothiadiazepine};$
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $\{N-[(R)-\alpha-[N-((S)-1\text{-carboxy-2-(R)-hydroxypropyl})\text{carbamoyl}]-4\text{-hydroxybenzyl}\}\text{carbamoylmethoxy}\}-2,3,4,5\text{-tetrahydro-1,2,5-benzothiadiazepine};$

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-{(S)-1-[*N*-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N*-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((R)- $\alpha$ -carboxy-4-hydroxybenzyl) carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Claims 7-8 (cancelled).

Claim 9 (currently amended): A method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a combination according to claim 1 ~~any one of claims 1-6~~.

Claim 10 (currently amended): A method of preventing diarrhoea that would result from excess bile acids in the intestine following administration of an effective amount an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, to a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a combination according to claim 1 ~~any one of claims 1-6~~.

Claim 11 (currently amended): A pharmaceutical composition which comprises a combination according to claim 1 ~~any one of claims 1-6~~, in association with a pharmaceutically acceptable diluent or carrier.

Claims 12-14 (cancelled).

Claim 15 (currently amended): A method of treating hyperlipidaemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises

administering to said animal an effective amount of a combination according to claim 1 ~~any one of claims 1-6~~.

Claims 16-18 (cancelled).

Claim 19 (currently amended): The combination according to claim 1 ~~any one of claims 1-6~~ further comprising an HMG Co-A reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.

Claim 20 (original): The combination according to claim 19 wherein the HMG Co-A reductase inhibitor is fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, dalvastatin, mevastatin and rosuvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Claim 21 (currently amended): The combination according to claim 1 ~~any one of claims 1-6~~ further comprising a cholesterol absorption antagonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.

Claim 22 (original): The combination according to claim 21 wherein the a cholesterol absorption antagonist is SCH 58235.

Claim 23 (currently amended): The combination according to claim 1 ~~any one of claims 1-6~~ further comprising a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof.

Claim 24 (original): The combination according to claim 23 wherein the PPAR alpha and/or gamma agonist is (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy)phenyl]propanoic acid and pharmaceutically acceptable salts thereof.

Claims 25-26 (cancelled).

Claim 27 (currently amended): A method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a composition according to claim 19 ~~any one of claims 19-24~~.

Claim 28 (currently amended): A pharmaceutical composition which comprises a combination according to claim 19 ~~any one of claims 19-24~~, in association with a pharmaceutically acceptable diluent or carrier.

Claims 29-31 (cancelled).

Claim 32 (original): A method of preventing diarrhoea that would result from excess bile acids in the intestine following administration of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, which comprises administering to a patient in need thereof, a metal salt, wherein the metal salt is formulated to release in the terminal ileum, caecum and/or the colon.